Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The global healthcare challenge of cancer remains challenging, requiring innovative approaches to identify potential anticancer agents. The intriguing anti-tumor properties of hydatid cysts produced in their larval stage by Echinococcus granulosus (E. granulosus) have attracted the attention of many scientists in recent years. This review aimed to delve deeper into the in vivo anticancer effects of hydatid cyst-derived antigens and shed light on their mechanisms of action and therapeutic implications for various cancer types. Several bioactive molecules in E. granulosus antigens have shown significant anti-cancer activity in vivo. Several studies have shown that administering these antigens reduced tumor size while increasing overall survival in breast cancer models. The immune response against tumor cells in lung cancer murine models has also been enhanced by E. granulosus antigens, such as antigen B, leading to the regression of tumors and enhanced immunity. Colon cancer cells are sensitized to these antigens as indicated by in vivo studies, rendering standard chemotherapy more effective at inhibiting tumor growth. E. granulosus antigens also reduce tumor metastasis when applied to in vivo melanoma models. E. granulosus antigens have demonstrated in vivo efficacy as a potential anticancer agent, underscoring their potential as valuable therapeutic agents. There is still much to be discovered about the exact mechanisms of these antigens and their clinical applicability. However, the impressive results observed across a wide range of cancer types underscore the significance of further research into the antigens to overcome cancer in vivo. In conclusion, animal model studies reveal the promising potential of E. granulosus antigens, particularly hydatid cyst fluid, in inhibiting tumor growth in colon, breast, melanoma, and lung cancers through immune-mediated mechanisms and apoptosis induction. These findings open up new avenues for cancer therapy and immunotherapy research, emphasizing the role of parasite antigens in combatting various cancer types.
The global healthcare challenge of cancer remains challenging, requiring innovative approaches to identify potential anticancer agents. The intriguing anti-tumor properties of hydatid cysts produced in their larval stage by Echinococcus granulosus (E. granulosus) have attracted the attention of many scientists in recent years. This review aimed to delve deeper into the in vivo anticancer effects of hydatid cyst-derived antigens and shed light on their mechanisms of action and therapeutic implications for various cancer types. Several bioactive molecules in E. granulosus antigens have shown significant anti-cancer activity in vivo. Several studies have shown that administering these antigens reduced tumor size while increasing overall survival in breast cancer models. The immune response against tumor cells in lung cancer murine models has also been enhanced by E. granulosus antigens, such as antigen B, leading to the regression of tumors and enhanced immunity. Colon cancer cells are sensitized to these antigens as indicated by in vivo studies, rendering standard chemotherapy more effective at inhibiting tumor growth. E. granulosus antigens also reduce tumor metastasis when applied to in vivo melanoma models. E. granulosus antigens have demonstrated in vivo efficacy as a potential anticancer agent, underscoring their potential as valuable therapeutic agents. There is still much to be discovered about the exact mechanisms of these antigens and their clinical applicability. However, the impressive results observed across a wide range of cancer types underscore the significance of further research into the antigens to overcome cancer in vivo. In conclusion, animal model studies reveal the promising potential of E. granulosus antigens, particularly hydatid cyst fluid, in inhibiting tumor growth in colon, breast, melanoma, and lung cancers through immune-mediated mechanisms and apoptosis induction. These findings open up new avenues for cancer therapy and immunotherapy research, emphasizing the role of parasite antigens in combatting various cancer types.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.